Diagnostic Tests drives the growth of Shigella Test Kit Market
Diagnostic Tests drives the growth of Shigella Test Kit Market
Asia Pacific is anticipated to be the fastest growing market for Shigella Test Kits, expanding at around 6.5% CAGR during 2023-2030 on back of increasing healthcare spending, growing middle-class population and rising awareness about waterborne diseases among consumers.

The Shigella Test Kit market is estimated to be valued at US$ 106.4 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

 

Market Overview:

Shigella test kits are diagnostic kits used to detect the presence of Shigella bacteria, which causes shigellosis or bacillary dysentery disease. The kits detect Shigella antigens in stool samples through immunochromatographic or enzyme-linked immunosorbent assay methods. They provide fast and reliable detection of Shigella infection compared to culture-based methods. This allows for quick treatment determination and control of outbreaks.

 

Market Dynamics:

The shigella test kit market is expected to witness significant growth over the forecast period owing to the rising incidence of shigellosis globally. As per the World Health Organization (WHO), India accounts for over 50% of global Shigella infections. There are an estimated 80-165 million cases of shigellosis each year globally. The increasing prevalence of the disease is boosting the demand for rapid and reliable diagnostic tests for detection of Shigella. Moreover, the growing need for point-of-care diagnosis and home testing for shigellosis is supporting adoption of immunochromatographic-based rapid diagnostic tests, fueling market growth. However, limitations in detection capabilities of antigen-based tests pose a challenge. Development of accurate and affordable molecular diagnostic tests can provide opportunities for market players.

 

SWOT Analysis

Strength:

- Shigella test kits aid in early detection and treatment of shigellosis, thereby helping to reduce the spread of the infection. The kits allow for rapid testing and results.

- Advanced technology used in Shigella test kits such as immunoassays and molecular assays improve testing accuracy and reliability.

- Increasing awareness about waterborne infections globally is boosting the demand for effective diagnostic solutions like Shigella test kits.

 

Weakness:

- High costs associated with advanced Shigella diagnostic kits limit their widespread adoption in cost-sensitive markets.

- Requirement of trained professionals for conducting certain molecular assays may pose challenges in resource-poor settings.

 

Opportunity:

- Growth opportunities in emerging economies in Asia Pacific and Latin America driven by rising investments in healthcare infrastructure and diagnostic capabilities.

- Increasing incidence of drug-resistant Shigella strains creates need for more accurate diagnostic methods for identifying resistant strains.

 

Threats:

- Stringent regulatory framework for approval of new diagnostic tests increases timeline and costs of product development and commercialization.

- Threat of substitute technologies that offer cheaper or more convenient testing mechanisms.

 

Key Takeaways

 

The global Shigella test kit market is expected to witness high growth, exhibiting CAGR of 5.9% over the forecast period, due to increasing incidence of shigellosis globally especially in developing regions with poor sanitation standards.

 

Regional analysis:

North America currently dominates the global market attributed to advanced healthcare infrastructure and availability of sophisticated diagnostic technologies. However, Asia Pacific is poised to be the fastest growing regional market for Shigella test kits driven by rising healthcare expenditure, large patient pools, and aggressive government initiatives to strengthen diagnostic capabilities.

 

Key players analysis:

Key players operating in the Shigella test kit market are Thermo Fisher Scientific Inc., Meridian Bioscience Inc., QIAGEN N.V., Bio-Rad Laboratories Inc., Creative Diagnostics, Hardy Diagnostics, Luminex Corporation, DiaSorin S.p.A., Sekisui Diagnostics LLC, BioMérieux SA, MP Biomedicals LLC, Coris BioConcept, Alere Inc., Fujirebio Diagnostics Inc., and CTK Biotech Inc. Major players are focused on launching novel diagnostic kits with improved accuracy and shorter turnaround times.

 

Read more

https://www.rapidwebwire.com/shigella-test-kit-market-size-share-growth-outlook-2023/

 

 

disclaimer

What's your reaction?

Comments

https://www.timessquarereporter.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!

Facebook Conversations